Laboratory for Advanced Medicine (LAM)
566 Nyes Place
18 articles with Laboratory for Advanced Medicine (LAM)
6/19/2020Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Laboratory for Advanced Medicine Announces New China CEO Position to Commercialize its Early Cancer Diagnostic for Liver and Colon Cancer Detection in Asia
Lifelong biotech leader Samuel Tong was a former executive in Asia of several large multinationals, including QIAGEN, Becton Dickinson and Abbott
Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the appointment of Benjamin Oyler as Chief Operating Officer
The former Amazon executive will further propel the company's growth and market expansion
Test's liver cancer detection is superior to current standard of care, new data supports
LAM's IvyGene Liquid Biopsy Platform Demonstrates High Diagnostic Capabilities In New Cancer Indication
LAM Announces Positive Results for Liquid Biopsy Test that Detects Early Stages of Nasopharyngeal Carcinoma at ASCO 2019 Annual Meeting
LAM Announces New Data Demonstrating High Diagnostic Potential Of Cell-Free DNA Methylation Assay For Early, Non-Invasive Detection Of Liver, Breast And Colorectal Cancers At AACR 2019
Study Data Demonstrate High Sensitivity And Specificity Of IvyGene Test In The Diagnosis Of Liver, Breast And Colorectal Cancers
LAM To Present Data For Cell-Free DNA Methylation Assay For Non-Invasive Diagnosis Of Liver, Breast And Colorectal Cancers At AACR Annual Meeting 2019
Data Showcase the High Diagnostic Potential of LAM's Circulating Cell-Free DNA Methylation Assay for the Early Detection of Multiple Cancers
Laboratory for Advanced Medicine to Present Data Demonstrating Efficacy of DNA Methylation as Epigenetic Biomarkers for Non-Invasive Breast Cancer Detection at Upcoming San Antonio Breast Cancer Symposium
Presentation showcases ability of blood-based DNA methylation to diagnose disease with high specificity and sensitivity
LAM Announces New Data Validating High Sensitivity and Specificity of DNA Methylation-Based Biomarkers for Noninvasive Diagnosis of Liver Cancer at SITC Meeting
Biomarkers demonstrate 95% sensitivity and 97.5% specificity in diagnosing hepatocellular carcinoma
LAM Announces Presentation of DNA Methylation-Based Biomarker Data for Noninvasive Diagnosis of Hepatocellular Carcinoma at SITC 2018
Presentation showcases ability of biomarkers to detect presence of disease with high specificity
7/16/2018With the Independence Day holiday in the rearview mirror, numerous biopharma companies continued to adjust their leadership ranks and strengthen the members of various boards representing and overseeing the companies.
Laboratory for Advanced Medicine announced that the Company has recently appointed Dr. Jinjie Hu as its Chief Regulatory Officer.
Dr. Kang Zhang, Chairman of Laboratory for Advanced Medicine Scientific Advisory Board, to Present at 2018 Liquid Biopsy Summit
Dr. Kang Zhang, Founding Director of Institute for Genomic Medicine at University of California San Diego and Chairman of LAM's Scientific Advisory Board, will present at The Liquid Biopsy Summit, taking place on June 20 through 22, 2018, in San Francisco.
Laboratory for Advanced Medicine (LAM) announced that Justin Li, General Manager and Vice President of Finance, will present at the 2018 BIO International Convention.
Laboratory for Advanced Medicine Commercializes Non-Invasive, Artificial Intelligence-Based IvyGene Blood Test for Early Cancer Detection
Company Expands Headquarters and National Workforce to Accommodate Rapid Growth
The following is a roundup of presentations and findings from multiple companies participating in the 2018 American Association for Cancer Research (AACR) in Chicago.
Laboratory for Advanced Medicine Presents Findings on Blood-Based Test for Liver Cancer Detection and Prognosis at 2018 AACR Annual Meeting
Results Demonstrate Utility of ctDNA Methylation Markers in Large Clinical Cohort